Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Synairgen ( (GB:SNG) ) has shared an announcement.
Synairgen plc announced the successful passing of resolutions at its General Meeting, leading to its re-registration as a private limited company and delisting from AIM. This strategic move involves appointing Asset Match to facilitate trading of its shares through an electronic off-market dealing facility, ensuring continued liquidity for shareholders. The transition reflects Synairgen’s ongoing efforts to streamline operations and adapt to market conditions, potentially impacting its industry positioning and stakeholder engagement.
More about Synairgen
Synairgen is a UK-based respiratory company focused on developing SNG001, an inhaled formulation of interferon beta, as a potential broad-spectrum antiviral treatment for severe viral lung infections. The company aims to address the global need for effective antiviral therapies, as millions are hospitalized annually due to viral lung infections, with no approved treatments currently available for most patients.
YTD Price Performance: -61.19%
Average Trading Volume: 1,416,042
Technical Sentiment Signal: Buy
Current Market Cap: £11.56M
For an in-depth examination of SNG stock, go to TipRanks’ Stock Analysis page.